Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

Safety Profile of Ruxolitinib in Patients With MF

Icahn School of Medicine at Mount Sinai

D. Tremblay

Top Risk Factors for Cancer by Sex and What to Do About It

MedCram

R. Seheult

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

ASH 2022 Conference Coverage

M. McMullin

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Insights from 2023 ASH Annual Meeting

D. Tremblay

Diagnosis and Goals of Therapy in PV

Northwestern Medicine Oncology and Hematology

B. Stein

Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…

Monia Marchetti

Treatment-Related Quality of Life in MF

Winship Cancer Institute - Emory University

A. Hunter

2021 ASCO Key Takeaways on Lymphoma: Selected Trials on CLL & HL, CA…

2021 ASCO Virtual Direct™ Highlights

M. Kamdar

ASCO 2022 Updates in Lymphoma and CLL

Total Health

W. Hammond

ASH Updates on cHL: 2L Pembro + GVD, Brentuximab Vedotin & Checkpoin…

UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

P. Riedell

Brentuximab Vedotin + AVD vs. ABVD in Advanced cHL: What Is the 5-Ye…

David Straus

SOHO 2021 Next Questions in Hodgkin Lymphoma

Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

C. Moskowitz

ASCO 2021 Q&A Session on Key Clinical Data in Leukemia & Lymphoma

2021 ASCO Virtual Direct™ Highlights

C. McMahon, M. Kamdar

UPenn Expert Discussion on Lymphoma: Efficacy of Acalabrutinib for S…

Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

S. Schuster, J. Gerson, J. Svoboda, E. Chong, S. Nasta, D. Beach, G. Hanna

Classical Hodgkin Lymphoma: Subtypes and Differential Diagnosis

Judith Ann Ferry

ASCO 2021 Q&A Session on New Updates in Hematologic Malignancies

2021 ASCO Virtual Direct™ Highlights

D. Maloney, M. Percival

Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL): Clinical an…

Judith Ann Ferry